Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 27, 2022

Trastuzumab With Trimodality Treatment for Oesophageal Adenocarcinoma With HER2 Overexpression

The Lancet Oncology


Additional Info

The Lancet Oncology
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial
Lancet Oncol 2022 Jan 14;na(na)na, HP Safran, K Winter, DH Ilson, D Wigle, T DiPetrillo, MG Haddock, TS Hong, LP Leichman, L Rajdev, M Resnick, LA Kachnic, S Seaward, H Mamon, DA Diaz Pardo, CM Anderson, X Shen, AK Sharma, AW Katz, J Salo, KL Leonard, J Moughan, CH Crane

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading